TY - JOUR T1 - Acute Peritoneal Dialysis During the COVID-19 Pandemic at Bellevue Hospital in New York City JF - medRxiv DO - 10.1101/2020.08.16.20175992 SP - 2020.08.16.20175992 AU - Nina J. Caplin AU - Olga Zhdanova AU - Manish Tandon AU - Nathan Thompson AU - Dhwanil Patel AU - Qandeel Soomro AU - Fnu Ranjeeta AU - Leian Joseph AU - Jennifer Scherer AU - Shivam Joshi AU - Betty Dyal AU - Harminder Chawla AU - Sitalakshmi Iyer AU - Doug Bails AU - Judith Benstein AU - David S. Goldfarb AU - Bruce Gelb AU - Richard Amerling AU - David M. Charytan Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/18/2020.08.16.20175992.abstract N2 - The COVID-19 pandemic created an unprecedented strain on hospitals in New York City. Although practitioners focused on the pulmonary devastation, resources for the provision of dialysis proved to be more constrained. To deal with these shortfalls, NYC Health and Hospitals/Bellevue, NYU Brooklyn, NYU Medical Center and the New York Harbor VA Healthcare System, put together a plan to offset the anticipated increased needs for kidney replacement therapy.Prior to the pandemic, peritoneal dialysis was not used for acute kidney injury at Bellevue Hospital. We were able to rapidly establish an acute peritoneal dialysis program at Bellevue Hospital for acute kidney injury patients in the intensive care unit. A dedicated surgery team was assembled to work with the nephrologists for bedside placement of the peritoneal dialysis catheters. A multi-disciplinary team was trained by the lead nephrologist to deliver peritoneal dialysis in the intensive care unit. Between April 8, 2020 and May 8, 2020, 39 peritoneal dialysis catheters were placed at Bellevue Hospital. 38 patients were successfully started on peritoneal dialysis. As of June 10, 2020, 16 patients recovered renal function. One end stage kidney disease patient was converted to peritoneal dialysis and was discharged. One catheter was poorly functioning, and the patient was changed to hemodialysis before recovering renal function. There were no episodes of peritonitis and nine incidents of minor leaking, which resolved. Some patients received successful peritoneal dialysis while being ventilated in the prone position.In summary, despite severe shortages of staff, supplies and dialysis machines during the COVID-19 pandemic, we were able to rapidly implement a de novo peritoneal dialysis program which enabled provision of adequate kidney replacement therapy to all admitted patients who needed it. Our experience is a model for the use of acute peritoneal dialysis in crisis situations.Competing Interest StatementDr. Charytan has consulted for Fresenius Medical Care and Medtronic, has received research support from Medtronic and Bioporto, and has received fees related to service on a trial committee from PLC Medical. Dr. Goldfarb has consulted for AstraZeneca.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NYU School of Medicine Institutional Review Board 1 Park Avenue | 6th Floor | New York, NY 10016All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnone ER -